AMGN vs. QGEN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMGN and QGEN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | AMGN | QGEN |
|---|---|---|
| Company Name | Amgen Inc. | Qiagen N.V. |
| Country | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 160.37 billion USD | 10.15 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 17, 1983 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of AMGN and QGEN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AMGN | QGEN |
|---|---|---|
| 5-Day Price Return | 8.73% | 6.51% |
| 13-Week Price Return | -0.12% | -3.19% |
| 26-Week Price Return | -4.38% | 16.56% |
| 52-Week Price Return | -6.83% | 5.52% |
| Month-to-Date Return | 5.56% | 4.74% |
| Year-to-Date Return | 14.29% | 5.10% |
| 10-Day Avg. Volume | 2.71M | 1.09M |
| 3-Month Avg. Volume | 2.44M | 1.40M |
| 3-Month Volatility | 26.15% | 23.36% |
| Beta | 0.46 | 0.68 |
Profitability
Return on Equity (TTM)
AMGN
97.92%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, AMGN’s Return on Equity of 97.92% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
QGEN
10.66%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
QGEN’s Return on Equity of 10.66% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
AMGN
18.96%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
AMGN’s Net Profit Margin of 18.96% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
QGEN
18.30%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
QGEN’s Net Profit Margin of 18.30% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
AMGN
24.01%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 24.01% places AMGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
QGEN
22.84%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
An Operating Profit Margin of 22.84% places QGEN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AMGN | QGEN |
|---|---|---|
| Return on Equity (TTM) | 97.92% | 10.66% |
| Return on Assets (TTM) | 7.35% | 6.40% |
| Net Profit Margin (TTM) | 18.96% | 18.30% |
| Operating Profit Margin (TTM) | 24.01% | 22.84% |
| Gross Profit Margin (TTM) | 69.71% | 64.18% |
Financial Strength
Current Ratio (MRQ)
AMGN
1.31
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
AMGN’s Current Ratio of 1.31 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
QGEN
1.61
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
QGEN’s Current Ratio of 1.61 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
AMGN
7.57
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 7.57, AMGN operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
QGEN
0.41
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
QGEN’s Debt-to-Equity Ratio of 0.41 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
AMGN
2.40
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
AMGN’s Interest Coverage Ratio of 2.40 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
QGEN
27.84
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
QGEN’s Interest Coverage Ratio of 27.84 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | AMGN | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 1.31 | 1.61 |
| Quick Ratio (MRQ) | 0.98 | 1.20 |
| Debt-to-Equity Ratio (MRQ) | 7.57 | 0.41 |
| Interest Coverage Ratio (TTM) | 2.40 | 27.84 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AMGN
3.06%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AMGN’s Dividend Yield of 3.06% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
QGEN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
AMGN
82.64%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 82.64%, AMGN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
QGEN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AMGN | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 3.06% | 0.00% |
| Dividend Payout Ratio (TTM) | 82.64% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
AMGN
24.19
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
AMGN’s P/E Ratio of 24.19 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
QGEN
27.10
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
QGEN’s P/E Ratio of 27.10 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
AMGN
4.59
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
AMGN’s P/S Ratio of 4.59 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
QGEN
4.96
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
QGEN’s P/S Ratio of 4.96 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
AMGN
20.21
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
AMGN’s P/B Ratio of 20.21 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
QGEN
2.97
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
QGEN’s P/B Ratio of 2.97 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | AMGN | QGEN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 24.19 | 27.10 |
| Price-to-Sales Ratio (TTM) | 4.59 | 4.96 |
| Price-to-Book Ratio (MRQ) | 20.21 | 2.97 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.59 | 20.40 |